Literature DB >> 1696296

Synthetic peptide vaccine against mucosal colonization by group A streptococci. I. Protection against a heterologous M serotype with shared C repeat region epitopes.

D Bessen1, V A Fischetti.   

Abstract

M protein is an antigenically variable virulence determinant present on the surface of group A streptococci, and it provides the basis for the serologic typing scheme. Type-specific serum antibodies afford strong protection against infection by the homologous serotype. Non-type-specific antigenic epitopes also exist within the surface-exposed portion of M protein. Previous studies demonstrated that intranasal immunization with Ag corresponding to sequences within the non-type-specific pepsin-susceptible site and adjacent C repeat regions of M6 protein, evoke protective immunity against pharyngeal colonization by type 6 streptococci in a mouse model. Although the protective immunogens are not type-specific, the pepsin site region of M6 is shared among less than 20% of serotypes examined. Therefore it was necessary to determine whether more highly conserved M protein epitopes elicit mucosal protection against group A streptococci, and if protective immunity extends to heterologous serotypes. In this report, peptides were synthesized that correspond to sequences completely contained within the highly conserved C repeat region of M6 protein. Peptide Ag were covalently coupled to the mucosal adjuvant, cholera toxin B subunit (CTB), and mice immunized intranasally and orally with peptide-CTB conjugates were compared to control groups that received CTB only. Immunization with the peptide-CTB conjugates led to significant protection against pharyngeal colonization by group A streptococci. Furthermore, protection was observed against the heterologous M serotype, type 14. These findings suggest that protection against multiple serotypes of group A streptococci can be achieved with a vaccine consisting of the widely shared C repeat region of M6 protein.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 1696296

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  36 in total

1.  Surface expression of the conserved C repeat region of streptococcal M6 protein within the Pip bacteriophage receptor of Lactococcus lactis.

Authors:  B L Geller; N Wade; T D Gilberts; D E Hruby; R Johanson; L Topisirovic
Journal:  Appl Environ Microbiol       Date:  2001-12       Impact factor: 4.792

2.  A lipid core peptide construct containing a conserved region determinant of the group A streptococcal M protein elicits heterologous opsonic antibodies.

Authors:  Colleen Olive; Michael R Batzloff; Anikó Horváth; Allan Wong; Timothy Clair; Penny Yarwood; Istvan Toth; Michael F Good
Journal:  Infect Immun       Date:  2002-05       Impact factor: 3.441

3.  Vaccination against rheumatic heart disease: a review of current research strategies and challenges.

Authors:  Manisha Pandey; Michael R Batzloff; Michael F Good
Journal:  Curr Infect Dis Rep       Date:  2012-08       Impact factor: 3.725

Review 4.  Strategies in the development of vaccines to prevent infections with group A streptococcus.

Authors:  Michael F Good; Michael R Batzloff; Manisha Pandey
Journal:  Hum Vaccin Immunother       Date:  2013-06-28       Impact factor: 3.452

5.  Host Pathways of Hemostasis that Regulate Group A Streptococcus pyogenes Pathogenicity.

Authors:  Victoria A Ploplis; Francis J Castellino
Journal:  Curr Drug Targets       Date:  2020       Impact factor: 3.465

6.  Immunological relationship between the class I epitope of streptococcal M protein and myosin.

Authors:  A Quinn; K Ward; V A Fischetti; M Hemric; M W Cunningham
Journal:  Infect Immun       Date:  1998-09       Impact factor: 3.441

Review 7.  Nasal lymphoid tissue, intranasal immunization, and compartmentalization of the common mucosal immune system.

Authors:  H Y Wu; M W Russell
Journal:  Immunol Res       Date:  1997       Impact factor: 2.829

8.  Novel conserved group A streptococcal proteins identified by the antigenome technology as vaccine candidates for a non-M protein-based vaccine.

Authors:  Andrea Fritzer; Beatrice M Senn; Duc Bui Minh; Markus Hanner; Dieter Gelbmann; Birgit Noiges; Tamás Henics; Kai Schulze; Carlos A Guzman; John Goodacre; Alexander von Gabain; Eszter Nagy; Andreas L Meinke
Journal:  Infect Immun       Date:  2010-07-12       Impact factor: 3.441

9.  Clearance of Pseudomonas aeruginosa from the murine gastrointestinal tract is effectively mediated by O-antigen-specific circulating antibodies.

Authors:  G B Pier; G Meluleni; J B Goldberg
Journal:  Infect Immun       Date:  1995-08       Impact factor: 3.441

10.  Immunogenicity in mice and non-human primates of the Group A Streptococcal J8 peptide vaccine candidate conjugated to CRM197.

Authors:  Ivette Caro-Aguilar; Elizabeth Ottinger; Robert W Hepler; Deborah D Nahas; Chengwei Wu; Michael F Good; Michael Batzloff; Joseph G Joyce; Jon H Heinrichs; Julie M Skinner
Journal:  Hum Vaccin Immunother       Date:  2012-12-18       Impact factor: 3.452

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.